본문 바로가기
KERD
논문KCI 등재

Discussion on critical points for a tailored therapy to cure hepatitis C virus infection

Nadia Marascio|Angela Quirino|Giorgio Settimo Barreca|Luisa Galati|Chiara Costa|Vincenzo Pisani|Maria Mazzitelli|Giovanni Matera|Maria Carla Liberto|Alfredo Focà|Carlo Torti
대한간학회 (The korean Association for the Study of the Liver)|2019.03|Clinical and Molecular Hepatology|제25권 제1호|pp. 30-36

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

Genetic variationDeep sequencingDirect-acting antiviralsResistance-associated substitutions

초록

Hepatitis C virus (HCV) infects around 71 million people worldwide and in 2018 it is still a major health problem. Since 2011, anti-HCV therapy with availability of direct-acting antiviral drugs has revolutionized the clinical response and paved the way to eradication strategies. However, despite the high rate of sustained virological response, treatment failure may occur in a limited percentage of patients, possibly due to resistance-associated substitutions (RASs), either emergent or pre-existent even in minority viral populations. Clearly this problem may impair success of eradication strategies. With this background, several questions marks still exist around HCV treatment, including whether pan-genotypic treatments with complete effectiveness in any clinical conditions really exist outside clinical trials, the actual cost-effectiveness of genotyping testing, and utility of RAS detection in viral quasispecies by next generation sequencing approach. In this review, we describe these critical points by discussing recent literature data and our research experience.

Abstract

Hepatitis C virus (HCV) infects around 71 million people worldwide and in 2018 it is still a major health problem. Since 2011, anti-HCV therapy with availability of direct-acting antiviral drugs has revolutionized the clinical response and paved the way to eradication strategies. However, despite the high rate of sustained virological response, treatment failure may occur in a limited percentage of patients, possibly due to resistance-associated substitutions (RASs), either emergent or pre-existent even in minority viral populations. Clearly this problem may impair success of eradication strategies. With this background, several questions marks still exist around HCV treatment, including whether pan-genotypic treatments with complete effectiveness in any clinical conditions really exist outside clinical trials, the actual cost-effectiveness of genotyping testing, and utility of RAS detection in viral quasispecies by next generation sequencing approach. In this review, we describe these critical points by discussing recent literature data and our research experience.

참고문헌 (52)

  1. Global hepatitis report 2017, "World Health Organization", World Health Organization, 83~ (2017)
  2. Calvaruso V, "Is global elimination of HCV realistic?", Liver Int, 38(Suppl 1), pp.40~46 (2018)
  3. Borgia SM, "Identification of a novel hepatitis C virus genotype from Punjab, India-expanding classification of hepatitis C virus into 8genotypes", J Infect Dis, 218, pp.1722~1729 (2018)
  4. Smith DB, "Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes : updated criteria and genotype assignment web resource", Hepatology, 59, pp.318~327 (2014)
  5. Domingo E, "Viral quasispecies evolution", Microbiol Mol Biol Rev, 76, pp.159~216 (2012)
  6. Kartashev V, "New findings in HCV genotype distribution in selected West European, Russian and Israeli regions", J Clin Virol, 81, pp.82~89 (2016)
  7. Liberto MC, "Epidemiological features and specificities of HCV infection: a hospital-based cohort study in a university medical center of Calabria region", BMC Infect Dis, 12(Suppl 2), pp.S4~ (2012)
  8. Marascio N, "Eleven-year distribution pattern of hepatitis C virus in southern Italy", J Pathog, 2012, pp.631095~ (2012)
  9. Chhatwal J, "Hepatitis C virus re-treatment in the era of direct-acting antivirals : projections in the USA", Aliment Pharmacol Ther, 47, pp.1023~1031 (2018)
  10. European Association for the Study of the Liver, "EASL recommendations on treatment of hepatitis C 2016", J Hepatol, 66, pp.153~194 (2017)
  11. Bartlett SR, "Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy : a systematic review", Hepatol Commun, 1, pp.379~390 (2017)
  12. Pawlotsky JM, "Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens", Gastroenterology, 151, pp.70~86 (2016)
  13. Korean Association for the Study of the Liver, "KASL clinical practice guidelines : management of hepatitis C", Clin Mol Hepatol, 22, pp.76~139 (2016)
  14. "HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C"[URL]
  15. Geddawy A, "Direct acting anti-hepatitis C virus drugs : clinical pharmacology and future direction", J Transl Int Med, 5, pp.8~17 (2017)
  16. Asselah T, "Direct- acting antivirals for the treatment of hepatitis C virus infection:optimizing current IFN-free treatment and future perspectives", Liver Int, 36(Suppl 1), pp.47~57 (2016)
  17. Omata M, "APASL consensus statements and recommendation on treatment of hepatitis C", Hepatol Int, 10, pp.702~726 (2016)
  18. Molino S, "Hepatitis C virus resistance testing in genotype 1 : the changing role in clinical utility", Ann Pharmacother, 51, pp.811~816 (2017)
  19. Bagaglio S, "Resistance mechanisms in hepatitis C virus : implications for direct-acting antiviral use", Drugs, 77, pp.1043~1055 (2017)
  20. Ito J, "Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection", Hepatol Res, 46, pp.1294~1303 (2016)
  21. Li Z, "Naturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China", Medicine (Baltimore), 96, pp.e6830~ (2017)
  22. Cuypers L, "Impact of HCV genotype on treatment regimens and drug resistance : a snapshot in time", Rev Med Virol, 26, pp.408~434 (2016)
  23. 조병욱, "Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study", Clinical and Molecular Hepatology, 23(1), pp.51~56 (2017), 대한간학회[DOI]
  24. Kliemann DA, "Genetic barrier to direct acting antivirals in HCV sequences deposited in the European databank", PLoS One, 11, pp.e0159924~ (2016)
  25. Ferenci P, "ABT-450", r-ombitasvir and dasabuvir with or without ribavirin for HCV, 2014, pp.370, 1983~1992
  26. Marascio N, "Real-life 3D therapy failure : analysis of NS5A 93H RAS plus 108K polymorphism in complex with ombitasvir by molecular modeling", J Med Virol, 90, pp.1257~1263 (2018)
  27. Struble K, "Benefit-risk assessment for sofosbuvir", velpatasvir, Hepatology, pp.2017[DOI]
  28. Poordad F, "Glecaprevir", Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure, 2018, pp.67, 1253~1260
  29. Carrion AF, "Glecaprevir + pibrentasvir for treatment of hepatitis C", Expert Opin Pharmacother, 19, pp.413~419 (2018)
  30. Pham LV, "HCV genotype 6a escape from and resistance to velpatasvir, pibrentasvir, and sofosbuvir in robust infectious cell culture models", Gastroenterology, 154, pp.2194~2208 (2018)
  31. Younossi ZM, "Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C : patientreported outcomes from POLARIS 2 and 3", Aliment Pharmacol Ther, 47, pp.259~267 (2018)
  32. Polilli E, "Consequences of inaccurate hepatitis C virus genotyping on the costs of prescription of direct antiviral agents in an Italian district", Clinicoecon Outcomes Res, 8, pp.467~473 (2016)
  33. Strazzulla A, "Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals", BMC Infect Dis, 14(Suppl 5), pp.S3~ (2014)
  34. Taherkhani R, "Global elimination of hepatitis C virus infection : progresses and the remaining challenges", World J Hepatol, 9, pp.1239~1252 (2017)
  35. Torti C, "Future research and collaboration: the “SINERGIE” project on HCV (South Italian Network for Rational Guidelines and International Epidemiology)", BMC Infect Dis, 12(Suppl 2), pp.S9~ (2012)
  36. Marascio N, "Update on epidemiology of HCV in Italy: focus on the Calabria Region", BMC Infect Dis, 14(Suppl 5), pp.S2~ (2014)
  37. Guadagnino V, "Hepatitis C virus infection in an endemic area of Southern Italy 14 years later : evidence for a vanishing infection", Dig Liver Dis, 45, pp.403~407 (2013)
  38. Marascio N, "Update on different aspects of HCV variability: focus on NS5B polymerase", BMC Infect Dis, 14(Suppl 5), pp.S1~ (2014)
  39. Stelzl E, "Evaluation of the new cobas(R)HCV genotyping test based on real-time PCRs of three different HCV genome regions", Clin Chem Lab Med, 55, pp.517~521 (2017)
  40. Ciccozzi M, "Hepatitis C virus genotype 4d in Southern Italy : reconstruction of its origin and spread by a phylodynamic analysis", J Med Virol, 84, pp.1613~1619 (2012)
  41. Marascio N, "Back to the origin of HCV 2c subtype and spreading to the Calabria region(Southern Italy)over the last two centuries : a phylogenetic study", Infect Genet Evol, 26, pp.352~358 (2014)
  42. Marascio N, "Detection of natural resistance-associated substitutions by ion semiconductor technology in HCV1b positive, direct-acting antiviral agents-naïve patients", Int J Mol Sci, 17, pp.E1416~ (2016)
  43. Sarrazin C, "Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir", Gastroenterology, 151, pp.501~512 (2016)
  44. Pineda-Peña AC, "Trends and predictors of transmitted drug resistance(TDR)and clusters with TDR in a local Belgian HIV-1 epidemic", PLoS One, 9, pp.e101738~ (2014)
  45. Cuypers L, "Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy", BMC Evol Biol, 17, pp.70~ (2017)
  46. -a web-based interpretation system to support hepatitis C treatment decisions in the era of direct-acting antiviral agents, "PLoS One", 2016, e0155869~
  47. Sarrazin C, "The importance of resistance to direct antiviral drugs in HCV infection in clinical practice", J Hepatol, 64, pp.486~504 (2016)
  48. Martell M, "Hepatitis C virus(HCV)circulates as a population of different but closely related genomes : quasispecies nature of HCV genome distribution", J Virol, 66, pp.3225~3229 (1992)
  49. Gaspareto KV, "Resistance-associated variants in HCV subtypes 1a and 1b detected by Ion Torrent sequencing platform", Antivir Ther, 21, pp.653~660 (2016)
  50. Zeuzem S, "NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus : prevalence and effect on treatment outcome", J Hepatol, 66, pp.910~918 (2017)
  51. Paolucci S, "Baseline and breakthrough resistance mutations in HCV patients failing DAAs", Sci Rep, 7, pp.16017~ (2017)
  52. Torti C, "Towards HCV extinction with modern HCV treatment? “Yes we can!”", BMC Infect Dis, 12(Suppl 2), pp.S1~ (2012)

관련 논문AI추천

Hepatitis C Virus and Antiviral Drug ResistanceKwang-Hyub Han, Sang Hoon Ahn, Seungtaek Kim거트앤리버 소화기연관학회협의회 · Gut and Liver2016 · 제10권 제6호Current and future strategies for the treatment of chronic hepatitis COmar Alshuwaykh, Paul Y. Kwo대한간학회 · Clinical and Molecular Hepatology2021 · 제27권 제2호Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failureAlessio Aghemo, Maria Corina Plaz Torres, Tommaso Lorenzo Parigi대한간학회 · Clinical and Molecular Hepatology2019 · 제25권 제4호Next-generation sequencing analysis of hepatitis C virus resistance–associated substitutions in direct-acting antiviral failure in South Korea안상훈, 이병석, 이연재, Eun Sun Jang, Hye Jung Park, In Hee Kim, Kyung-Ah Kim, Sejoon Lee, Seungtaek Kim, Sook Hyang Jeong, Sung Bum Cho, Woo Jin Chung, Young Suk Kim대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제2호Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapyChung-Feng Huang, Ming-Lung Yu대한간학회 · Clinical and Molecular Hepatology2020 · 제26권 제3호Acute hepatitis C virus infection: clinical update and remaining challengesChen-Hua Liu, Jia-Horng Kao대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제3호

이 간행물의 다른 논문 (10건)

Recent research trends and updates on nonalcoholic fatty liver disease이진우, 조용균, 김원, Sang Hoon Park, Moon Young Kim, 김상균, Jong Eun Yeon, Joo Hyun Sohn, Jeong-Ju Yoo, KASL-KNSGpp. 1-11Pathologic differential diagnosis of metastatic carcinoma in the liver김정호, Jeong Hwan Parkpp. 12-20Radiomics and radiogenomics of primary liver cancersNeema Jamshidi, Woo Kyoung Jeong, Ely Richard Felker, Steven Satish Raman, David Shinkuo Lupp. 21-29Biomarker microfibril-associated glycoprotein 4 for non-invasive diagnosis and therapeutic evaluation of hepatic fibrosis in patients with hepatitis C엄영우, 백순구pp. 37-39Can hepatic steatosis really promote hepatitis B viral hepatocarcinogenesis? The jury is out on.김원pp. 40-41
원문 보기